Venrock's new 5.6% passive stake signals institutional interest but no activist intent. Monitor for any future conversion to Schedule 13D or additional purchases that could indicate a shift in strategy.
Price Chart
Executive Summary
Venrock Healthcare Capital Partners III, L.P. and affiliated entities filed a new Schedule 13G disclosing a 5.6% passive stake in X4 Pharmaceuticals, Inc., representing 5,555,047 shares of common stock as of September 14, 2026. This is a new filing (not an amendment) by a healthcare-focused venture capital firm, indicating a meaningful passive position in the company.
Key Financial Metrics
Key Facts
- Venrock Healthcare Capital Partners III, L.P. and affiliates filed a new Schedule 13G on September 21, 2026.
- The reporting persons beneficially own 5,555,047 shares of X4 Pharmaceuticals common stock.
- The stake represents 5.6% of shares outstanding, based on 99,146,743 shares outstanding as of July 31, 2026.
- The filing certifies the securities were not acquired with the purpose of changing or influencing control of the issuer.
- This is a new filing, not an amendment to a prior 13G.
Financial Impact
Passive 5.6% stake valued at approximately $5.6 million based on current market price (not disclosed in filing).
Risk Factors
- Venrock could later convert to an activist 13D filing, though the current filing explicitly disclaims control intent.
- The small market cap of X4 Pharmaceuticals makes it vulnerable to dilution or adverse clinical/regulatory events.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0001738048-26-000071 |
| Exhibit: ex-24-09222026_120952.htm | 0001738048-26-000071 |
| Exhibit: ex-24-09222026_120951.htm | 0001738048-26-000071 |
| Document: 0001738048-26-000071-index-headers.html | 0001738048-26-000071 |
| Document: 0001738048-26-000071-index.html | 0001738048-26-000071 |
| Document: 0001738048-26-000071.txt | 0001738048-26-000071 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 8-K | $2.91 | awaiting T+20 | — | $3.25 (+11.68%) |
Oct 7, 2026 19d ago | SC 13G/A | $2.81 | awaiting T+20 | — | $3.25 (+15.66%) |
Oct 1, 2026 25d ago | 144 | $2.83 | awaiting T+20 | — | $3.25 (+14.84%) |
Sep 21, 2026 5w ago | SC 13G | $3.43 $3.02 | ▼ −11.95% | ▼ −11.39% | $3.25 (−5.25%) |
Sep 8, 2026 6w ago | 8-K | $3.51 $2.77 | ▼ −20.97% | ▼ −22.68% | $3.25 (−7.28%) |
Aug 13, 2026 10w ago | Insider Cluster | $4.22 $3.62 | ▼ −14.22% | ▼ −12.23% | $3.25 (−22.99%) |
Aug 13, 2026 10w ago | 144 | $4.29 $3.50 | ▼ −18.41% | ▼ −16.67% | $3.25 (−24.24%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.88 $3.96 | ▲ +2.06% | ▲ +0.17% | $3.25 (−16.24%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.88 $3.96 | ▲ +2.06% | ▲ +0.17% | $3.25 (−16.24%) |
May 18, 2026 23w ago | EFFECT | $3.68 $4.04 | ▲ +9.78% | ▲ +8.20% | $3.25 (−11.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers